Although the knowledge of checkpoint expression on γδ T cells is still sparse, our observations of an increased frequency of TIGIT+ γδ T cells confirm the data of increased levels of TIGIT+ γδ T cells in de novo AML patients published by Jin et al. In their study, upregulation of TIGIT on γδ T cells was associated with a lower overall survival rate for non-M3 AML (38). Here, TIGIT is linked to acute myeloid leukemia.